drugset / Trial / NCT05055726

Benzydamine Oromucosal Solution in Oral Mucositis (BOOM)

NCT05055726

Phase 4 Completed 100 enrolled Angelini Pharma PPD Development, LP · collab
NaSingle-groupOpen-labelTreatment

Summary

The aim of the present study is to collect data on the feasibility of a preventative/therapeutic approach of radiation-induced oral mucositis with benzydamine oromucosal solution (mouthwash) in patients with head and neck cancer.

Timeline

Start
2021-12-06
Primary completion
2022-09-05
Completion
2022-09-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Benzydamine Unknown 0.15 % Other
Subject Benzydamine Unknown 15 ml Other